Prognostic Significance of Plasma High-Sensitivity C-Reactive Protein in Patients With Hypertrophic Cardiomyopathy.
Prognostic Significance of Plasma High-Sensitivity C-Reactive Protein in Patients With Hypertrophic Cardiomyopathy.
复制标题
肥厚型心肌病患者血浆高敏C反应蛋白的预后意义
DOI：
10.1161/jaha.116.004529
复制
发表时间：
2017-02-02
影响因子：
5.4
通讯作者：
Wang J
中科院分区：
文献类型：
--
作者：
Zhu L;Zou Y;Wang Y;Luo X;Sun K;Wang H;Jia L;Liu Y;Zou J;Yuan Z;Hui R;Kang L;Song L;Wang J
高敏 C 反应蛋白 (hsCRP) 升高与各种心血管疾病不良后果的风险增加有关。 hsCRP 与肥厚型心肌病预后之间的关系仍有待评估。该研究采用了观察队列方法。 2001年至2011年间，阜外医院共有490名患者入组，随访时间为3.7±2.0年。根据hsCRP的风险类别，高hsCRP组（>3.0 mg/L）的受试者比低hsCRP组（<1.0 mg/L）发生不良事件的风险更高：心血管死亡（调整后的危险比[HR] 5.41，95% CI 1.96-14.93，P=0.001）、全因死亡率（调整后的HR 4.78， 95% CI 1.99–11.47，P<0.001）、心源性猝死（调整后 HR 11.29，95% CI 1.38–92.20，P=0.024）和心力衰竭相关死亡（调整后 HR 4.38，95% CI 1.15–16.60，P=0.030）。同样，hsCRP 连续变量也是不良结局的独立预测因子：心血管死亡（调整后 HR 1.15，95% CI 1.06-1.25，P=0.001）、全因死亡率（调整后 HR 1.17，95% CI 1.09-1.26，P<0.001）、心源性猝死（调整后 HR 1.20，95% CI 1.06-1.36，P=0.003），以及心力衰竭相关死亡（调整后的 HR 1.15，95% CI 1.02-1.30，P=0.020）。我们的研究结果表明，血浆 hsCRP 升高与肥厚型心肌病患者不良结局风险增加相关。
Elevated high‐sensitivity C‐reactive protein (hsCRP) has been associated with increased risks of adverse outcomes of various cardiovascular diseases. The relationship between hsCRP and the prognosis of hypertrophic cardiomyopathy remains to be evaluated. The study used an observational cohort methodology. A total of 490 patients were enrolled in the Fuwai Hospital from 2001 to 2011 and were followed for 3.7±2.0 years. According to the risk category of hsCRP, subjects in the high hsCRP group (>3.0 mg/L) had a higher risk of developing adverse events than the low hsCRP group (<1.0 mg/L): cardiovascular death (adjusted hazard ratios[HR] 5.41, 95% CI 1.96–14.93, P=0.001), all‐cause mortality (adjusted HR 4.78, 95% CI 1.99–11.47, P<0.001), sudden cardiac death (adjusted HR 11.29, 95% CI 1.38–92.20, P=0.024), and heart failure–related death (adjusted HR 4.38, 95% CI 1.15–16.60, P=0.030). Similarly, the continuous variable of hsCRP was also an independent predictor for adverse outcomes: cardiovascular death (adjusted HR 1.15, 95% CI 1.06–1.25, P=0.001), all‐cause mortality (adjusted HR 1.17, 95% CI 1.09–1.26, P<0.001), sudden cardiac death (adjusted HR 1.20, 95% CI 1.06–1.36, P=0.003), and heart failure–related death (adjusted HR 1.15, 95% CI 1.02–1.30, P=0.020). Our results indicate that elevated plasma hsCRP is associated with increased risk for adverse outcomes in patients with hypertrophic cardiomyopathy.